SCHEMBL13102414

SCHEMBL13102414

Cc1nc2c(Cl)cccc2c(=O)n1NC(=O)Cc1ccc(F)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
KMT2A Q03164 4/20 0.47
LMNA P02545 3/20 0.47
HTT P42858 3/20 0.47
MEN1 O00255 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
MAPT P10636 1/20 0.41
CYP2D6 P10635 1/20 0.41
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PDE7A Q13946 2/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13101724 0.89 ALDH1A1 (0.46) ALDH1A1KMT2ALMNAHTTMEN1
SCHEMBL13101726 0.89 ALDH1A1 (0.46) ALDH1A1KMT2ALMNAHTTMEN1
SCHEMBL13102418 0.89 ALDH1A1 (0.52) ALDH1A1KMT2ALMNAHTTMEN1
SCHEMBL13102063 0.87 ALDH1A1 (0.46) ALDH1A1KMT2ALMNAHTTMEN1
SCHEMBL13101731 0.85 ALDH1A1 (0.57) ALDH1A1KMT2ALMNAHTTMEN1
SCHEMBL13102221 0.84 ALDH1A1 (0.44) ALDH1A1KMT2ALMNAHTTMEN1
SCHEMBL13101706 0.80 ALDH1A1 (0.44) ALDH1A1KMT2ALMNAHTTMEN1
SCHEMBL13102381 0.79 ALDH1A1 (0.55) ALDH1A1KMT2ALMNAHTTMEN1
SCHEMBL13101705 0.78 ALDH1A1 (0.43) ALDH1A1KMT2ALMNAHTTMEN1
SCHEMBL13102399 0.77 ALDH1A1 (0.42) ALDH1A1KMT2ALMNAHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329713-B2 Fused ring heterocycles as potassium channel modulators ICAGEN INC. (US) 2012-12-11 US disclosed
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNK17, KCNJ2, KCNJ1 ALDH1A1 2354/4885KMT2A 1295/4885LMNA 1121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.